FINWIRES · TerminalLIVE
FINWIRES

TYO:4507

11 stories mentioning TYO:4507Updated 46d ago

Every FINWIRES story that references TYO:4507, newest first.

What are analysts saying about TYO:4507?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on TYO:4507?

Asia

Market Chatter: Shionogi Eyes At Least Three Acquisitions, Plans US Expansion

Shionogi & Co (TYO:4507) is scouting for at least three acquisition targets in the infectious and rare diseases sector across the U.S., Japan and Europe, Bloomberg News reported Thursday, citing Chairman and CEO Isao Teshirogi in a recent interview.The Japanese drugmaker is also weighing U.S. manufacturing expansion to mitigate geopolitical risks over the next decade, Teshirogi said, saying the company has significant financial capacity to fund deals, the news outlet reported.Last year, Shionogi completed three acquisitions worth a combined 880 billion yen, Reuters said.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

TYO:4507
Asia

Shionogi & Co. Profit Rises 91% in Fiscal Q1

Shionogi & Co. (TYO:4507) posted a 90.5% year-over-year increase in profit attributable to owners of the parent to 97.7 billion yen for the fiscal first half ended June 30 from 39.4 billion yen.The pharmaceutical company's revenue rose 48% to 163.3 billion yen from 99.8 billion yen in the year prior, according to a Tokyo Stock Exchange filing on Monday.For the fiscal year ending March 31, 2027, the company forecasts an attributable profit of 210 billion yen and revenue of 700 billion yen.

TYO:4507
Asia

Shionogi's Attributable Profit Up 148% in Fiscal Q1

Shionogi's (TYO:4507) attributable profit to owners jumped 148% during the fiscal first quarter ended June 30 to 97.7 billion yen from 39.3 billion yen a year earlier, according to a Monday filing with the Tokyo Exchange.Diluted earnings per share came in at 114.78 yen compared with 46.25 yen in the year-ago period.Revenue surged 64% year over year to 163.3 billion yen from 99.8 billion yen.The pharmaceutical company forecasted an attributable profit of 108 billion yen, basic earnings per share of 126.91 yen and a revenue of 340 billion yen for the fiscal six months ending Sept. 30.

TYO:4507
Research

Jefferies Upgrades Shionogi to Buy From Hold, Adjusts Price Target to 3,800 Yen From 3,700 Yen

Shionogi (TYO:4507) has an average rating of overweight and mean price target of 3,388.46 yen, according to analysts polled by FactSet.

TYO:4507
Asia

Shionogi Board Approves 568 Million Yen Treasury Share Disposal Under Restricted Stock Compensation Plan

Shionogi & Co. (TYO:4507) board approved the disposal of 201,300 treasury shares totaling up to 567.6 million yen under its restricted stock compensation plan.The shares were allocated to two directors, excluding audit & supervisory committee member directors and outside directors; 15 corporate officers; and 60 vice presidents, according to a Wednesday filing on the Tokyo Stock Exchange.The disposal will be completed on July 23.

TYO:4507
Asia

Shionogi Secures Approval for Pediatric Dosage of COVID-19 Drug Xocova in Japan

Shionogi & Co. (TYO:4507) said it secured supplemental approval for the pediatric dosage and administration of its Xocova drug for the treatment of COVID-19 in Japan, according to a Friday release.The Japan-based pharmaceutical company said that the approval expands the drug's usage among pediatric patients aged 6 to under 12 years who weigh at least 20 kilograms.The approval also covers a new 25-milligram tablet and follows results from a Phase 3 clinical trial involving 117 children in Japan.

TYO:4507
Asia

Shionogi & Co's New Antifungal Pill Shows Promising Results in Late-Stage Trial

Shionogi & Co (TYO:4507) and F2G reported positive late-stage trial results for their antifungal pill olorofim, tested in patients with invasive aspergillosis who cannot use standard azole treatments.The trial found that olorofim worked just as well as the current intravenous treatment, with similar survival rates at 42 days-about 76% of patients in both groups were still alive, according to a Tokyo bourse filing on Thursday.Importantly, the new pill caused far fewer side effects, especially kidney-related problems, which are a major concern with existing therapies.The drug already holds FDA Breakthrough status, and the companies now plan to file for regulatory approval in the US, Europe, and Asia.If approved, this would be the first new class of antifungal medicine in over 20 years, offering a much-needed oral alternative for vulnerable patients with weak immune systems.

TYO:4507
Research

Goldman Sachs Upgrades Shionogi & Co to Buy from Neutral; Price Target is 3,400 Yen

Shionogi & Co (TYO:4507) has an average rating of overweight and mean price target of 3,392.31 yen, according to analysts polled by FactSet.

TYO:4507
Asia

Shionogi & Co Secures US FDA Approval for Oral Antiviral to Prevent COVID-19 After Exposure

The US Food and Drug Administration approved Shionogi & Co's (TYO:4507) Xocova or ensitrelvir as the first and only oral antiviral for post-exposure prophylaxis of COVID-19 in individuals aged 12 and older, according to a Tokyo bourse filing on Monday.The approval, which came ahead of the June 16 Prescription Drug User Fee Act action date, was supported by Phase 3 Scorpio-PEP trial results, which showed a 67% reduction in symptomatic COVID-19 risk following exposure compared to placebo.The treatment was generally well tolerated, with adverse event rates similar to placebo, and no reports of altered taste attributed to the drug.

TYO:4507
Asia

Shionogi Covid Pill Reduced Infection Risk in Late-Stage Study

Shionogi & Co's (TYO:4507) oral antiviral ensitrelvir significantly reduced the risk of COVID-19 infection among household contacts of infected patients in a phase 3 post-exposure prophylaxis trial, according to study results published Wednesday.The randomized, double-blind, placebo-controlled study enrolled more than 2,000 participants across Japan, assigning them to receive either ensitrelvir or placebo within 72 hours of symptom onset in an index case. By day 10, COVID-19 occurred in 2.9% of those receiving ensitrelvir versus 9.0% in the placebo group, corresponding to a risk reduction of about 67%.The safety profile was broadly comparable between the two groups, with similar rates of adverse events and no COVID-19-related hospitalisations or deaths reported during the trial.Ensitrelvir is already approved in Japan for the treatment of mild-to-moderate COVID-19, and the company said the findings support its potential use in preventing infection following household exposure.

TYO:4507
Asia

Shionogi to Absorb Torii Pharmaceutical in April 2027 Merger

Shionogi & Co (TYO:4507) will absorb its wholly owned subsidiary Torii Pharmaceutical through an absorption-type merger effective April 1, 2027, as it moves to strengthen integration and decision-making, according to a Monday filing on the Tokyo Stock Exchange.The companies signed the merger agreement on April 27 following board approval the same day.Shionogi will remain the surviving entity, while Torii Pharmaceutical will be dissolved, with no new shares or cash consideration issued as part of the transaction.The company said the merger will deepen collaboration and enhance synergies, particularly in therapeutic areas such as allergy and dermatology.

TYO:4507

Track with the FINWIRES app suite

FolioX
FolioX
Track TYO:4507 in your portfolio
WheelAI
WheelAI
Analyze TYO:4507 options with the wheel strategy
StockInsider
StockInsider
See market sentiment on TYO:4507